Badheeb najran cancer unit 2013
•Download as PPT, PDF•
1 like•1,308 views
This document discusses the establishment of a multidisciplinary cancer care unit at King Khalid Hospital in Najran, Saudi Arabia. It aims to provide comprehensive cancer treatment using evidence-based guidelines. The cancer unit has several goals, including becoming a training center and establishing a cancer registry. It has developed phases to expand its services from medical and surgical oncology initially to include nuclear medicine and radiation oncology. A multidisciplinary tumor board follows guidelines to determine the best diagnostic and treatment approaches for patients. The importance of a multidisciplinary approach is emphasized to determine personalized treatment plans tailored to each patient.
Recommended
Recommended
More Related Content
What's hot
What's hot (20)
Viewers also liked
Viewers also liked (11)
Similar to Badheeb najran cancer unit 2013
Similar to Badheeb najran cancer unit 2013 (20)
More from Prof. Ahmed Mohamed Badheeb
More from Prof. Ahmed Mohamed Badheeb (20)
Recently uploaded
Recently uploaded (20)
Badheeb najran cancer unit 2013
- 1. Towards Multidisciplinary Cancer Care at KKH- Najran Ahmed Badheeb , MD. Professor Of Oncology & internal medicine King Khalid Hospital- Najran
- 2. Objectives • • • • Cancer : the size of the problem in Najran Cancer unit : the goals. The Tumor Board at KKH: functions & guidelines The importance of multidisciplinary approach.
- 3. Cancer in Saudi Arabia : 2004
- 4. Cancer in Saudi Arabia : by sex
- 5. Cancer in Saudi Arabia : by age
- 6. Cancer in Saudi Arabia : by ASR
- 10. There is an urgent need for Cancer registry • Saudi Cancer Registry (population based). • Hospital based registry
- 11. Objectives • Cancer : the size of the problem in Najran • Cancer unit : the goals. • The Tumor Board at KKH: functions & guidelines • The importance of multidisciplinary approach.
- 12. Goals of the oncology Service: • A comprehensive evidence based cancer (including the psycho-social care). • To be a nucleus for the upcoming cancer center. • Training Centre for the doctors, medical students, nurses ,pharmacists, social workers, etc. • Cancer registry service (both hospital based & population based). • Cancer research .
- 13. Phases of the development • Phase (I): Medical & surgical oncology (?). • Phase(II): Nuclear medicine • Phase (III): addition of radiation oncology service.
- 14. Phase : 1
- 18. VAD team
- 19. Safe handling of chemotherapy
- 20. Social support
- 21. Your diagnosis is cancer !!
- 24. Palliative care & pain management
- 25. Modified WHO Analgesic Ladder Quality of Life Invasive treatments Proposed 4 th Step Opioid Delivery Pain persisting or increasing Step 3 Opioid for moderate to severe pain ± Nonopioid ± Adjuvant Pain persisting or increasing The WHO Ladder Step 2 Opioid for mild to moderate pain ± Nonopioid ± Adjuvant Pain persisting or increasing Step 1 ± Nonopioid ± Adjuvant Pain Deer, et al., 1999
- 26. Cancer research unit • Epidemiologists • Bio- statistician
- 30. Procedure Room
- 31. KHH lab upgrade
- 33. Flowcytometry
- 34. Cytogenetics
- 35. Phase II
- 36. Phase II Bone Scan Patient A Multiple bone metastase s
- 37. Phase: III
- 38. Phase: III
- 39. Objectives • Cancer : the size of the problem in Najran • Cancer unit : the goals. • The Tumor Board at KKH: functions & guidelines • The importance of multidisciplinary approach.
- 40. Function To approve the best evidence based multidisciplinary diagnostic & therapeutic approach for tumor cases.
- 41. Multidisciplinary Tumor Board Surgical, medical & radiation oncologists, radiologists, pathologists, nuclear medicine, and coordinator nurses , social worker & psychologist specialists
- 42. Saudi cancer Guidelines NCCN • Modified from • Written by the most expert oncologists in the country in each branch.
- 43. What is the NCCN? An Alliance of 21 Academic Cancer Centers in USA
- 44. NCCN Levels of Evidence • Category 1: Based upon high-level evidence and uniform NCCN consensus that intervention is appropriate • Category 2A: Based on lower-level evidence and uniform NCCN consensus that it constitutes appropriate care • Category 2B: Based upon lower-level evidence and NCCN consensus that it constitutes appropriate care • Category 3: Any level of evidence but major NCCN disagreement that the recommendation is appropriate.
- 45. Examples from Breast Cancer Guideline
- 46. Objectives • • • • Cancer : the size of the problem in Najran Cancer unit : the goals. The Tumor Board at KKH: functions & guidelines The importance of multidisciplinary approach.
- 47. Fundamental questions When is surgery enough? Should we use chemotherapy? difficult to reverse practice Which treatment should we use? toxicity-many 'equal' therapies efficacy dosage
- 48. What is the best for the patient? Neoadjuvant ? Adjuvant ? •M astectomy vs. lumpectomy •Lymph node dissection vs. sentinel lymph node biopsy
- 49. Sentinel Lymph Node Biopsy 2. Track the lymphatic drainage of the
- 50. Personalized Oncology Ligand Ligand EGFr dimer Signal Adapters and Enzymes Grb-2 Shc SOS Grb-2 P13K MAPK = mitogen-activated protein kinase PTEN P13k = phosphatidylinositol 3-kinase SOS Ras Raf Akt MEK 1/2 Signal mTOR Transcription Factors FKHR GSK-3 Cascade BAD MAPK p27 Jun Cyclin D-1 FOS Myc
- 51. Thank you
Editor's Notes
- Proposed 4th step – looking at quality of life, changing opioid delivery, looking at invasive treatments
- There is evidence for the involvement of EGFR in the progression of CRC. Expression is stronger in tumor than normal mucosa [1] and strongest in tumor regions of deepest invasion [2,3]. EGFR expression correlates with the ability of CRC cells to produce hepatic metastases [4], and EGFR expression was shown to be higher in tumors of more advanced stage [5,6]. Mayer et al showed that pts with EGFR-expressing tumors (>50% of tumors stained) had a shorter median survival than those with non EGFR-expressing tumors (8.7 vs 34.0 mths, p<0.02) [7]. EGFR expression on liver metastases was shown to be a predictor of disease-free survival after partial liver resection [8]. EGFR is expressed in 25–77% of CRC [1,9]. EGFR is expressed in 72–86% of MCRC [2,10–12]. Messa C, Russo F, Caruso MG, Di Leo A. Acta Oncol 1998; 37:285–289. Goldstein NS, Armin M. Cancer 2001; 92:1331–1346. Spano J-P, Atlan D, Lagorce C, et al. Ann Oncol 2002; 13 Suppl 5:72. Radinsky R. Cancer Met Rev 1995; 14:323–328. Kluftinger AM, Robinson BW, Quenville NF, et al. Surg Oncol 1992; 1:97–105. Steele RJ, Kelly P, Ellul B, et al. Br J Surg 1990; 77:1352–1354. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. Cancer 1993; 71:2454–2460. De Jong KP, Stellema R, Karrenbeld A, et al. Hepatology 1998; 28:971–979. Salomon DS, Brandt R, Ciardiello F, Normanno N. Crit Rev Oncol Hematol 1995; 19:183–232. Lutz MP, Schöffski P, Folprecht G, et al. Ann Oncol 2002; 13 Suppl 5:73. Saltz L, Rubin M, Hochster H, et al. Proc Am Soc Clin Oncol 2001; 20: Abstract 7. Cunningham D, Humblet Y, Siena S, et al. Proc Am Soc Clin Oncol 2003; 22: Abstract 1012.